Observational Study to Find How Often Patients Develop High Ammonia Levels From Recombinant Erwinia Asparaginase and Identify Those at Risk

What this Trial Is About

This research aims to determine how often patients develop symptomatic hyperammonemia, which means high ammonia levels, when treated with recombinant Erwinia asparaginase. It also seeks to identify which patients are more at risk for this condition. The study focuses on patients with hematopoietic and lymphatic system neoplasms, including acute lymphoblastic leukemia. This is an observational study where patients receive their usual care while researchers collect information. Participants undergo blood sample collection, complete surveys, and have their medical records reviewed to gather data related to their treatment with recombinant Erwinia asparaginase. Participants will be monitored for up to 12 months to track the incidence of hyperammonemia. Throughout the study, researchers will review blood test results, questionnaires, and medical records to understand patient risk factors and outcomes. No treatment is altered for study purposes, and data collection supports understanding the conditions development during therapy.

A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase